Cardiff Oncology

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cardiff Oncology reports strong Q3 performance and strategic growth plans

Cardiff Oncology's Q3 2023 performance reflects strong progress with positive data from their lead program and promising efficacy of onvansertib, supported by a solid financial position.
While the company faces challenges in maintaining clinical trial progress and managing expenses, strategic strengths like the expanded partnership with Pfizer and focus on shareholder value creation position them well for future growth.
Opportunities lie in advancing their lead program, exploring new therapeutic indications, and leveraging collaborations to drive market penetration and enhance competitiveness in the oncology space.

Cardiff Oncology reports strong Q4 performance and strategic advancements

Cardiff Oncology's Q4 2023 earnings call highlighted a strategic shift in their mCRC program, positive clinical data from the ONSEMBLE trial, and a strong financial position. While facing challenges in addressing various analyst inquiries, the company is well-positioned to capitalize on opportunities in expanding their treatment portfolio and leveraging trial data for market differentiation.

Cardiff Oncology reports positive data and strong financial position

Cardiff Oncology's Q1 2024 earnings call highlighted positive data on onvansertib, ongoing trials, and a healthy financial position. Challenges include trial enrollment pace and follow-up data requirements. However, the company has opportunities for growth through successful trials and leveraging preclinical data.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , April 12, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Katherine L. Ruffner, M.D.

Cardiff Oncology Announces Departure of Chief Medical Officer

Trial evaluates onvansertib in combination with abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients showing initial abiraterone resistance by rising PSA Disease control increased with increasing dose density of onvansertib from 29% to 45% of patients achieving PSA stabilization and from 53% to 75% of patients with radiographic stable disease; Arm A (n=17) – onvansertib 24mg/m2 days 1-5 in 21-day cycle to Arm C (n=20) – 12mg/m2 days 1-14 in 21-day cycle Median progression-free survival (mPFS) has increased with increasing onvansertib dose density from 4.1 months in Arm A to 13.2 months to-date in Arm C patients Genomic analysis of ctDNA showed a correlation between alterations in two key genes of the PI3K signaling pathway—MTOR and PTEN, which appears to underly increased pathway activity, and sensitivity to onvansertib/abiraterone combination in mCRPC patients with early abiraterone resistance SAN DIEGO, April 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced updated clinical data and new biomarker analyses from its ongoing Phase 2 trial of onvansertib in combination with abiraterone/prednisone in metastatic castrate-resistant prostate cancer (mCRPC) patients. The data are featured in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place both virtually and in-person at the Ernest N.

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting

- Combining onvansertib with the PARP inhibitor (PARPi) olaparib led to statistically significant survival benefits compared to treatment with either agent alone in PARPi-resistant ovarian cancer models - Onvansertib-olaparib combination was well tolerated in vivo SAN DIEGO, April 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the results of preclinical studies evaluating the anti-cancer activity of onvansertib in combination with the PARP inhibitor (PARPi) olaparib in PARPi-resistant patient-derived xenograft (PDX) ovarian cancer models. The results are featured in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place both virtually and in-person at the Ernest N.

Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models

SAN DIEGO, March 22, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that CEO Mark Erlander, Ph.D., has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28 th – 30th from 9:00 AM - 5:00 PM EDT.

Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC

SAN DIEGO, March 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans, Louisiana from April 8-13, 2022.

Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting

Cardiff has done well in a Phase 2 study using onvansertib + FOLFIRI + Avastin in treating KRAS-mutated metastatic colorectal cancer patients with a 29% objective response rate.

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

SAN DIEGO, March 1, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a panel discussion and one-on-one investor meetings at Cowen's 42nd Annual Healthcare Conference taking place virtually March 7-9, 2022.   Details on the panel can be found below.

Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced recent company highlights and financial results from the fourth quarter and full year ended December 31, 2021. "Our recent progress has provided additional clinical and external validation of onvansertib, including a Pfizer Breakthrough Growth Initiative collaboration," said Mark Erlander, Ph.D.

Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights

Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that company management will present and participate in one-on-one meetings at the B. Riley Securities 2022 Oncology Conference, taking place virtually January 27 – 28, 2022.

Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference

Leap Therapeutics

These clinical-stage biotech stocks are headed in opposite directions today.

These 2 Nasdaq Stocks Are Poised to Make Big Moves Today

Cardiff Oncology Inc (NASDAQ: CRDF) posted new data from Phase 1b/2 trial of onvansertib combined with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line KRAS-mutated metastatic colorectal cancer (mCRC). The data will be shared at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Cardiff Oncology Slumps On New Data From Lead Program In Metastatic Colorectal Cancer

SAN DIEGO, Jan. 18, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced new data from its lead clinical program evaluating onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). A subset of these data will be featured in a poster presented by Dr. Heinz-Josef Lenz, principal investigator, USC Norris Comprehensive Cancer Center, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCOGI) on Saturday, January 22, 2022.

Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, RPh, as senior vice president, regulatory affairs.

Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that it will be hosting a conference call and webcast to discuss updated data from its lead clinical program in KRAS-mutated metastatic colorectal cancer on Tuesday, January 18, 2022, at 5:00 PM ET. Details on the conference call and webcast can be found below.

Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Aurinia Pharmaceuticals

Axsome Therapeutics

These three stocks are poised for a major breakout in 2022.

My 3 Top Biopharma Stock Picks for 2022

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that company management will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 10 – 13, 2022.

Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference

Cardiff has one asset, onvansertib, a PLK1 inhibitor which has performed well in the clinic thus far in second line KRAS-mutated mCRC.

Cardiff: The Pfizer Interest Is Interesting

TechnipFMC

Patterson-UTI Energy

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 ‘Strong Buy' Stocks Trading Under $10 With Huge Upside Potential

SAN DIEGO, Dec. 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that updated data from its lead KRAS-mutated metastatic colorectal cancer program will be featured in a poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI). ASCO-GI is taking place January 20-22, 2022, both virtually and in-person at the Moscone West Building in San Francisco, California.

Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

SAN DIEGO, Dec. 3, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that on December 2, 2021, non-qualified stock option awards to purchase an aggregate of 200,112 shares of its common stock were granted to two new employees. The stock options were granted as inducements material to the new employees becoming employees of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology is a prime takeover target heading into 2022.

1 Cancer Stock on Buyout Watch in 2022

The clinical-stage oncology specialist is getting an infusion of cash from pharmaceutical giant Pfizer.

Why Cardiff Oncology Shares Were Up More Than 15% on Thursday

Pfizer Inc (NYSE: PFE) has made a $15 million equity investment in Cardiff Oncology Inc (NASDAQ: CRDF) as part of the Pfizer Breakthrough Growth Initiative. Pfizer purchased 2.4 million shares of Cardiff Oncology's shares at $6.22 per share.

Cardiff Oncology Stock Rises After $15M Equity Investment From Pfizer

The stock price of Cardiff Oncology Inc (NASDAQ: CRDF) increased by over 19% pre-market today. This is why it happened.

News for Cardiff Oncology Stock (CRDF)